Adherex Licenses GSK’s Eniluracil, Estimates Oncologic’s Potential At $1 Bil.

Adherex gains rights to GlaxoSmithKline's oncology agent eniluracil in exchange for a GSK option on Adherex' lead biotechnology oncologic ADH-1 under a combined licensing agreement, announced July 15